Markets:

Overview

News

Currencies

International

Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

27.53 -0.41 (-1.47%)

Streaming Delayed Price Updated: 1:17 PM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Travere Therapeutics: Q4 Earnings Insights ↗

February 24, 2022

Travere Therapeutics (NASDAQ:TVTX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:01 PM. Here's what investors need to know about the announcement....

Via Benzinga

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

Travere Therapeutics's Earnings: A Preview ↗

February 23, 2022

Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement....

Via Benzinga

Earnings Scheduled For October 28, 2021 ↗

October 28, 2021

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •...

Via Benzinga

Earnings Scheduled For July 29, 2021 ↗

July 29, 2021

Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade ↗

February 14, 2022

Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Travere Posts Topline Data For Pegtibatinase In patients With Rare Metabolic Disorder ↗

December 15, 2021

Travere Therapeutics Inc (NASDAQ: TVTX) reported topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase for classical homocystinuria (HCU)....

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 28, 2021

Gainers Bellerophon Therapeutics (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗

October 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...

Via Benzinga

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗

October 24, 2021

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...

Via Benzinga

PleasrDAO Aint Nothing To F*** With: Wu Tang Clan Album Once Owned By Shkreli Has Been Purchased ↗

October 22, 2021

From the slums of Shaolin, Wu-Tang Clan strikes again. An exclusive album made by the legendary hip-hop group is back in the news ...

Via Benzinga

8 Health Care Stocks With Unusual Options Alerts In Today's Session ↗

September 16, 2021

This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away...

Via Benzinga

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study ↗

September 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...

Via Benzinga

Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand

September 16, 2021

From Vifor Pharma Group

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 15, 2021

Gainers Larimar Therapeutics (NASDAQ:

Via Benzinga

See Why Travere Therapeutics Stock Moving Higher On Tuesday ↗

September 07, 2021

Travere Therapeutics Inc (NASDAQ: TVTX) has concluded a Type A meeting with the FDA related to sparsentan in focal segmental glomerulosclerosis (FSGS). See:...

Via Benzinga

Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet ↗

August 16, 2021

Toward the end of trading Monday, the Dow traded up 0.03% to 35,526.99 while the NASDAQ fell 0.34% to 14,771.91. The S&P also rose, gaining 0.02% to 4,468.88. The U.S. has the...

Via Benzinga

Topics Stocks

60 Biggest Movers From Yesterday ↗

August 17, 2021

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of...

Via Benzinga

Here's Why Travere Therapeutics Stock Is Climbing Today ↗

August 16, 2021

Investors are cheering positive phase 3 trial results with sparsentan that suggest it could become an important new treatment for a rare kidney disease.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 16, 2021

Gainers NanoVibronix (NASDAQ:NAOV) stock rose 44.04% to $3.63 during Monday's regular session. The current volume of 150.7 million shares is 972.43% of NanoVibronix...

Via Benzinga

Mid-Day Market Update: Crude Oil Down Over 2%; Travere Therapeutics Shares Jump ↗

August 16, 2021

Midway through trading Monday, the Dow traded down 0.36% to 35,388.46 while the NASDAQ fell 1.24% to 14,639.36. The S&P also fell, dropping 0.54% to 4,443.76. The U.S. has the...

Via Benzinga

Topics Stocks

38 Stocks Moving In Monday's Mid-Day Session ↗

August 16, 2021

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares climbed 34.5% to $3.3900 after the company announced plan to expand product portfolio with introduction of Painshield relief for...

Via Benzinga

TVTX Stock: Why Travere Therapeutics Stock Is Rocketing Higher Today ↗

August 16, 2021

Travere Therapeutics (TVTX) stock is on the rise Monda and it's all thanks to positive interim results from one of its clinical trials.

Via InvestorPlace

Mid-Morning Market Update: Markets Open Lower; Empire State Manufacturing Index Dips In August ↗

August 16, 2021

Following the market opening Monday, the Dow traded down 0.40% to 35,372.03 while the NASDAQ fell 1.27% to 14,634.24. The S&P also fell, dropping 0.57% to 4,442.47. The U.S....

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 16, 2021

Gainers ADMA Biologics (NASDAQ:ADMA) stock rose 18.79% to $1.77 during Monday's pre-market session. The company's market cap stands at $226.8 million. The company...

Via Benzinga

Travere Therapeutics Stock Is Trading Higher On Positive Data From Kidney Disease Candidate ↗

August 16, 2021

Compared to the active control irbesartan, the study met its pre-specified interim primary efficacy endpoint, demonstrating a more than threefold reduction of proteinuria from...

Via Benzinga

10 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗

August 02, 2021

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...

Via Benzinga

Travere Therapeutics: Q2 Earnings Insights ↗

July 29, 2021

Shares of Travere Therapeutics (NASDAQ:TVTX) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 77.27% over...

Via Benzinga

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗

July 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

All News about Travere Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today